Sector News

Novartis plots 400 job cuts in India after striking sales pact with Dr. Reddy’s

February 20, 2022
Life sciences

A bid to boost access to Novartis’ drugs in India is putting hundreds of jobs on the chopping block.

Novartis India has forged an exclusive sales and distribution pact with Dr. Reddy’s Laboratories centered on certain established meds, including the pain-relief drug Voveran and Methergine, which is used to treat severe bleeding from the uterus after childbirth.

The pact is meant to broaden access to the meds beyond their current geographies, which Novartis and Dr. Reddy’s will accomplish “by significantly extending the reach of healthcare professionals through an expanded field force,” Novartis said. The deal will fuse Novartis India’s manufacturing and development know-how with Dr. Reddy’s sales and distribution muscle, the company said.

Novartis India plans to cut 400 jobs with the move. The company says it understands “the implications of this difficult decision,” so it’s offering employees a severance package and outplacement services.

Novartis employs more than 10,000 full-time staffers in India, the company said. Since January 2020, the company has hired more than 1,600 employees worldwide. Novartis’ Indian outfits plan to continue this hiring push in 2022, the company noted.

Meanwhile, Novartis is investing to upgrade its R&D and manufacturing footprint in the country. Over the past five years, it has spent more than $300 million on an Indian R&D support center, for instance.

Elsewhere in the country, the company is building out a $49 million manufacturing plant at Kalwe, which will manufacture oral cancer meds for the global market.

The Dr. Reddy’s news comes as Novartis conducts a strategic review of its generic unit, Sandoz. Investor groups Blackstone and Carlyle could join forces on a massive $25 billion bid for Sandoz, Bloomberg has said, citing people close to the matter. Novartis says it will provide an update on its plan for the generics outfit by the end of the year.

by Fraiser Kansteiner

Source: fiercepharma.com

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.